Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
MWN-AI** Summary
Prothena Corporation plc (NASDAQ: PRTA) announced that Novo Nordisk plans to advance Coramitug (formerly PRX004), an investigational amyloid depleter antibody, into Phase 3 development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). This decision follows a successful Phase 2 trial and aims to address a significant unmet medical need in patients suffering from this condition, which is associated with high rates of morbidity and mortality due to amyloid deposits in vital organs.
Coramitug is designed to selectively deplete amyloid without affecting the normal tetrameric form of the protein, thereby potentially improving organ function. Its proposed mechanism of action involves clearing deposited amyloid and preventing further accumulation, which sets it apart from existing therapies that stabilize or mitigate the production of the native TTR protein.
Under the agreement with Novo Nordisk, Prothena stands to earn up to $1.2 billion in potential milestone payments, including $100 million already secured. Prothena awaits a clinical milestone payment tied to targeted enrollment criteria in the upcoming Phase 3 trial.
Prothena, recognized for its expertise in protein dysregulation, continues to advance a pipeline aimed at transforming the treatment landscape for neurodegenerative and rare amyloid-related diseases. The company is focusing on conditions like ATTR amyloidosis, Alzheimer’s, and Parkinson’s disease, striving to leverage its deep scientific insights into the biology of misfolded proteins.
Potential developments in the clinical landscape of coramitug signal a promising direction in the treatment of ATTR amyloidosis, enhancing Prothena's portfolio, and paving the way for innovative therapeutic options. For further details, Prothena encourages visiting their website and following their updates on social platforms.
MWN-AI** Analysis
Prothena Corporation plc (NASDAQ:PRTA) recently announced that Novo Nordisk intends to advance coramitug (formerly PRX004) into Phase 3 development for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). This is significant for investors as coramitug represents a promising first-in-class amyloid depleter antibody and addresses an unmet medical need in a patient population facing early mortality risk due to amyloid deposition.
The positive results from the Phase 2 trial bolster the potential for coramitug to demonstrate clinical effectiveness in larger populations. Pending the successful initiation of the Phase 3 program in 2025, investors should closely monitor enrollment milestones, which could yield a $100 million clinical milestone payment for Prothena. With an additional $1.2 billion possible through other milestones, the development pathway appears lucrative.
Moreover, Prothena's unique approach with coramitug to deplete amyloid deposits without affecting the native TTR protein could position it favorably in the existing treatment landscape.
However, stakeholders should remain cognizant of potential risks. The biotech industry is inherently volatile, with factors such as regulatory approvals, clinical trial outcomes, and competitive dynamics posing substantial risks to stock performance. The forward-looking statements issued by Prothena also highlight uncertainties that could impact timelines and expectations.
Investors may consider adding Prothena to their portfolios, given the positive developments surrounding coramitug. However, maintaining a diversified portfolio and a clear exit strategy is prudent. As Prothena progresses through the trial phases, continuous assessment of clinical outcomes, market conditions, and regulatory news will be critical in guiding investment decisions. Overall, while the prospects are promising, caution and close observation of the evolving landscape are advisable.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3
- Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025
- Prothena to earn a clinical milestone payment when prespecified enrollment criteria are met in a Phase 3 clinical trial by Novo Nordisk
Prothena Corporation plc (NASDAQ:PRTA), announced that Novo Nordisk communicated during their second quarter 2025 earnings call on August 6, 2025 that they expect to advance coramitug, a potential first-in-class amyloid depleter antibody, into a Phase 3 program for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Coramitug was initially developed by Prothena and was acquired by Novo Nordisk in July 2021.
“We are excited by Novo Nordisk’s decision to advance coramitug into Phase 3 development. There remains a significant unmet need in patients with ATTR amyloidosis with cardiomyopathy, who are at high risk for early mortality and significant morbidity due to amyloid deposition in vital organs,” said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena.
Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion dollars upon achievement of clinical development and sales milestones, including the $100 million earned to date. Prothena is eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the Phase 3 clinical trial. Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021.
About Coramitug (formerly PRX004)
Coramitug (formerly PRX004) is an investigational antibody designed to deplete amyloid associated with disease pathology in hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein 1-3 . Coramitug’s proposed mechanism of action is to deplete both the deposited amyloid to improve organ function and circulating non-native TTR to prevent further organ deposition 1-3 . In preclinical studies, coramitug or its murine form demonstrated ability to inhibit amyloid fibril formation, bind soluble aggregate forms of non-native TTR and promote clearance of insoluble amyloid fibrils through antibody-mediated phagocytosis 1,2 . In a Phase 1 clinical study, coramitug was well tolerated in patients with ATTRv amyloidosis and demonstrated potential clinical activity on Global Longitudinal Strain (GLS) and Neuropathy Impairment Score (NIS) 3 . This differentiated depleter mechanism of action could be developed as a monotherapy approach to ATTR amyloidosis and might also complement existing therapeutic approaches which either stabilize or reduce production of the native TTR tetramer 3 .
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, the treatment potential, design, and proposed mechanism of action coramitug; plans for ongoing and future clinical trials of coramitug; and amounts we might receive under our agreement with Novo Nordisk. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 4, 2025, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
References:
1 Preclinical studies of PRX004 (coramitug) – data on file
2 Higaki JN et al. Amyloid , 2016
3 Suhr OB et al., Amyloid , 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250806119323/en/
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
FAQ**
How does Prothena Corporation plc PRTA plan to leverage Novo Nordisk's advancements with coramitug in future clinical trials for ATTR amyloidosis and potentially other indications?
What is the anticipated timeline for Prothena Corporation plc PRTA to receive milestones from Novo Nordisk, especially regarding the Phase 3 trial of coramitug?
Can Prothena Corporation plc PRTA provide insights on the primary goals and expected outcomes for coramitug during its Phase 3 trial, especially concerning its mechanism of action in amyloid depletion?
What strategies does Prothena Corporation plc PRTA have in place to address the risks and uncertainties highlighted in their recent SEC filings while progressing coramitug through clinical development?
**MWN-AI FAQ is based on asking OpenAI questions about Prothena Corporation plc (NASDAQ: PRTA).
NASDAQ: PRTA
PRTA Trading
-4.37% G/L:
$9.64 Last:
242,431 Volume:
$9.70 Open:
